Compounds > 9-(dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1-2]thieno[3-4-d]pyrimidinone

9-(dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1-2]thieno[3-4-d]pyrimidinone and Neuralgia

9-(dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1-2]thieno[3-4-d]pyrimidinone has been researched along with Neuralgia* in 2 studies

Other Studies

2 other study(ies) available for 9-(dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1-2]thieno[3-4-d]pyrimidinone and Neuralgia

ArticleYear
Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain.
    Bioorganic & medicinal chemistry letters, 2012, Feb-15, Volume: 22, Issue:4

    A series of fused tricyclic mGluR1 antagonists containing a pyridone ring were synthesized. In vitro, these antagonists were potent against both human and rat isozymes, as well as selective for inhibiting mGluR1 over mGluR5. When dosed orally, several examples were active in vivo in a rat SNL test.

    Topics: Administration, Oral; Analgesics; Animals; Cells, Cultured; Cyclization; Humans; Inhibitory Concentration 50; Molecular Structure; Neuralgia; Protein Binding; Pyridones; Rats; Receptors, Metabotropic Glutamate

2012
Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain.
    Bioorganic & medicinal chemistry letters, 2009, Jun-15, Volume: 19, Issue:12

    Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the SNL pain model with ED(50)s 3.3 and 6.4 mg/kg respectively. Metabolic outcome of propargyl amino moiety was studied.

    Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Neuralgia; Pyridines; Pyrimidines; Rats; Receptors, Metabotropic Glutamate; Structure-Activity Relationship

2009